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ABSTRACT
Introduction: The development of malignant pleural
effusion (MPE) results in disabling breathlessness,
pain and reduced physical capability with treatment a
palliative strategy. Ambulatory management of MPE
has the potential to improve quality of life (QoL). The
OPTIMUM trial is designed to determine whether full
outpatient management of MPE with an indwelling
pleural catheter (IPC) and pleurodesis improves QoL
compared with traditional inpatient care with a chest
drain and talc pleurodesis. OPTIMUM is currently open
for any centres interested in collaborating in this study.
Methods and analysis: OPTIMUM is a multicentre
non-blinded randomised controlled trial. Patients with a
diagnosis of MPE will be identified and screened for
eligibility. Consenting participants will be randomised
1:1 either to an outpatient ambulatory pathway using
IPCs and talc pleurodesis or standard inpatient
treatment with chest drain and talc pleurodesis as per
British Thoracic Society guidelines. The primary
outcome measure is global health-related QoL at
30 days measured using the EORTC QLQ-C30
questionnaire. Secondary outcome measures include
breathlessness and pain measured using a 100 mm
Visual Analogue Scale and health-related QoL at 60
and 90 days. A sample size of 142 patients is needed
to demonstrate a clinically significant difference of 8
points in global health status at 30 days, for an 80%
power and a 5% significance level.
Ethics and dissemination: The study has been
approved by the NRES Committee South East Coast—
Brighton and Sussex (reference 15/LO/1018). The trial
results will be published in peer-reviewed journals and
presented at scientific conferences.
Trial registration numbers: UKCRN19615 and
ISRCTN15503522; Pre-results.
INTRODUCTION
Malignant pleural effusion (MPE) is a
common presentation in advanced
malignancy, complicating nearly 50% of all
lung and breast cancers.1 Extrapolated data
estimate 50 000 new cases of MPE per year in
the UK, translating to one new case per 1000
population per year.2 MPE results in signiﬁ-
cant morbidity, including disabling breath-
lessness, pain and reduced physical
capability. With advancement of techniques
over the last decade, physicians and patients
are faced with a number of choices in the
management of MPE. These choices depend
on many factors, and not all patients are suit-
able for every strategy. Regardless of the
choice, the aim should be an overall
improvement in quality of life (QoL).
Managing patients with an easily imple-
mented ambulatory pathway which averts the
need for an inpatient hospital stay may
improve QoL in a population with an
Strengths and limitations of this study
▪ This is the first prospective randomised con-
trolled trial primarily comparing quality of life
(QoL) outcomes between inpatient and out-
patient treatment pathways for malignant pleural
effusion.
▪ The primary outcome measure is clinically
relevant.
▪ Patients with non-expandable lung are also
included in the study.
▪ The study represents real life presentation and
management.
▪ A limitation is that patients with poor perform-
ance status are not included and only patients
with potential for ambulatory management are
included. However, to include those patient
groups a separate study design to answer that
specific question will have to be conducted.
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otherwise poor prognosis.3 To investigate this, the
OPTIMUM trial, a National Institute for Health
Research (NIHR) Portfolio multicentre study (UKCRN
19615), is currently open to taking on other recruiting
sites.
British Thoracic Society guidelines
The 2010 British Thoracic Society (BTS) pleural disease
guideline advocates chest tube drainage and chemical
pleurodesis involving a hospital admission.4 The sclero-
sant of choice in the UK is graded large-particle talc, a
safe and effective sclerosant at a dose of 4 g.4 Median
length of a hospital admission for this intervention is
4 days (IQR 2–6 days).5
The indwelling pleural catheter
An alternative and increasingly popular strategy to
manage MPE is the insertion of an indwelling pleural
catheter (IPC) as an outpatient and continued manage-
ment on an outpatient/ambulatory basis. The BTS
recognises that IPCs are effective in controlling recur-
rent effusions and are particularly useful in cases of
trapped lung, where talc pleurodesis is likely to fail. It is
a safe procedure which can be managed in the out-
patient setting, thus avoiding hospital admission.6
A relatively new treatment pathway involves instillation
of talc via an IPC to prevent recurrence, allowing the
opportunity to manage people as outpatients. This novel
pathway in the management of MPE is well established
at Guy’s and St Thomas’s Hospital. Our case series of 24
patients who underwent talc pleurodesis via an IPC con-
ﬁrms the safety and efﬁcacy of this treatment algorithm7
on which the OPTIMUM trial is based.
A huge body of research has looked into the thera-
peutic management of MPE. This has led to multiple
management pathways. However, there is no one deﬁni-
tive management strategy. Despite the goal of palliation,
the majority of studies focus on outcome measures such
as pleurodesis success rate, failure rate and complica-
tions.6 8–12 While this is important, we believe it is
important to understand the impact of these interven-
tions on the overall well-being of patients.
There is a paucity of data on QoL outcomes in this
population, particularly the effects of different pleural
interventions. A retrospective study of talc pleurodesis
by surgical video-assisted thoracoscopy failed to show
any QoL beneﬁt at 3 and 6 months.13 The Second
Therapeutic Intervention in Malignant Effusion
(TIME2) randomised controlled trial showed no differ-
ence between medical pleurodesis and IPC insertion
without talc in relieving breathlessness. Global QoL eval-
uated as a secondary measure did improve in both
groups at 6 weeks, but there was no signiﬁcant differ-
ence in QoL at any time point.5 There are no prospect-
ive randomised controlled trials primarily comparing
QoL outcomes in the outpatient and inpatient manage-
ment of MPE.
OBJECTIVES
Hypothesis
The primary hypothesis is that outpatient management
of MPEs with an IPC improves global health-related QoL
at 30 days following insertion when compared to stand-
ard treatment according to BTS guidelines.
With no validated QoL assessment tools for patients
with MPE, global health-related QoL as measured by the
EORTC QLQ-C30 has been selected as the primary
outcome measure. It is an extensively used tool and vali-
dated for malignant disease of various histological
types.14 Using one tool to assess health-related QoL will
ensure that the protocol limits the burden to trial
participants.
Primary and secondary objectives and outcome mea-
sures are summarised in table 1.
METHODS AND ANALYSIS
Trial design
The OPTIMUM trial is a prospective, two-arm non-
blinded randomised multicentre trial. The Medicines
and Healthcare products Regulatory Agency have
cleared this trial as a non-clinical trial of investigational
medicinal product (non-CTIMP) study. All patients pre-
senting to recruitment centres with MPEs who fulﬁl the
inclusion criteria will be approached. The trial is cur-
rently open at eight sites in the UK: St Thomas’
Hospital, London; King’s College Hospital, London;
Princess Royal Hospital, Bromley; East Surrey Hospital,
Redhill; East Sussex Hospital, Eastbourne; St George’s
Hospital, London; Hull Royal Inﬁrmary, Hull and
Medway Maritime Hospital, Gillingham. At the time of
publication, we are actively seeking more sites to recruit.
Study population
A total of 142 patients in participating respiratory
departments meeting the eligibility criteria will be
recruited. All sites have a dedicated pleural service with
experience in IPC insertion.
Inclusion criteria
1. Diagnosis of MPE.i
2. WHO performance status 2 or less unless perform-
ance status is impaired by the presence of effusion
and likely to signiﬁcantly improve with drainage.
3. Expected survival <3 months.
Exclusion criteria
1. Age <18 years old.
2. Pregnant or lactating.
3. Known allergy to talc or lignocaine.
4. Lack of symptomatic relief from effusion drainage.
iHistocytological evidence of pleural malignancy. If a histocytological
diagnosis cannot be obtained, clinical correlation combined with
radiological features and primary tumour histology can be used to
make the diagnosis.
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5. District nurse/carers/hospital team unable to carry
out at least twice weekly drainage from an IPC.
6. Lymphoma or small cell carcinoma except:ii
A. Failure of chemotherapy.
B. Deemed for palliative management.
7. Non-malignant effusions.
8. Loculated pleural effusion that would prevent suc-
cessful drain insertion and clinical beneﬁt to the
patient.
9. Unable to provide written informed consent to trial
participation.
Recruitment and randomisation
Enrolment started in July 2015 and is anticipated to con-
tinue until January 2020. In each centre, the trial team
will screen patients presenting to the respiratory and
oncology clinics as well as inpatient wards.
Once screening procedures have conﬁrmed a patient’s
eligibility, they will be approached and consented for the
study. They will undergo stratiﬁed randomisation (1:1) to
either usual care as per BTS guidance or treatment with
an IPC. This will be performed using a web-based secure
randomisation service for clinical trials (http://www.
sealedenvelope.com). The stratiﬁcation variables are age
(<65 years, ≥65 years), malignancy subtype (lung, meso-
thelioma, breast, other) and WHO performance status
(0, 1, 2, 3). Given the nature of the intervention, patients
and the research team will not be blinded.
Study procedure
Table 2 outlines the schedule of enrolment, interven-
tions and assessments. Patients will undergo baseline
chest X-ray and ultrasound assessment. QoL and
symptom data will be collected using the EORTC
QLQ-C30 questionnaire, MRC Dyspnoea Scale and
100 mm Visual Analogue Score (VAS) for pain and
breathlessness. These questionnaires will be repeated for
both groups during each follow-up visit.
The indwelling pleural catheter group
The IPC intervention algorithm is summarised in
ﬁgure 1. Patients allocated to the IPC group will
undergo chest ultrasound to assess the pleura, pleural
ﬂuid and to identify a safe site for insertion.
The IPC will be inserted as per normal practice.9
Once the indwelling catheter is inserted, intrapleural
pressure will be measured with a water manometer
(Mediﬁx Manometer Scale, B. Braun, Shefﬁeld, UK),
and an attempt will be made to evacuate as much ﬂuid
as is tolerated while monitoring the patient’s symptoms
and oxygen saturation. Serial measurements of pleural
pressure will be recorded for every 500 mL of ﬂuid
drained continuing drainage until one of three criteria
is met:
1. Effusion fully drained.
2. Patient symptomatic with pain, cough or presyncope.
3. End expiratory pleural pressure drops below
20 cm H2O or pleural elastance >10 (pleural ela-
stance is calculated by dividing the change in pleural
pressure by the volume (in litres) removed).
Table 1 Primary and secondary objectives for the OPTIMUM trial
Objectives Outcome measures
Time points of
evaluation
Primary objective
To assess whether a minimally invasive evidence-based
pathway for the outpatient management of malignant
pleural effusion improves global health-related quality of
life at 30 days
Self-reported health-related quality of life based
on EORTC QLQ-C30 questionnaire
Day 30
Secondary objectives
Improvement in global health-related quality of life at 60
and 90 days
Self-reported health-related quality of life based
on EORTC QLQ-C30 questionnaire
Day 60, 90
Pleurodesis failure rate Subsequent pleural intervention required on the
same side as pleurodesis
Chest X-ray opacification greater than 25% on
side of intervention judged by two independent
clinicians
Day 30, 60, 90
Improvement in symptoms of pain and breathlessness Medical Research Council (MRC) Dyspnoea
Scale
100 mm Visual Analogue Scale for pain and
breathlessness
Day 30, 60 and
90
Complication rate Clinical review and adverse event
documentation
Day 7, 14, 30,
60 and 90
iiLymphoma and small cell carcinoma are particularly sensitive to
treatment with chemotherapeutic agents. If patients have undergone
chemotherapy with no treatment response or deemed not for
chemotherapy and for palliative management, then they will be
suitable for inclusion in the study. Liason with the patient’s oncologist
or multi-disciplinary team discussion will be required to ascertain this.
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Table 2 Schedule of enrolment, interventions and assessments
Both
groups Usual care group IPC group
Study procedures
Consent/
baseline Postrandomisation
Days
2–5
Day
7
Day
14
Day 30,
60, 90 Postrandomisation
Day
4
Day
7
Day
14
Day 30,
60, 90
Ongoing
(between
follow-up)
Sign consent X
Demographics/medical history/blood
pressure
X
Randomisation X
Local anaesthesia X X
Ultrasound-guided IPC or chest drain
insertion
X X
Pleural manometry X X
Daily observations (HR, respiratory rate,
oxygen requirement, BP, chest drain
assessment) drain in situ
X
Inpatient drainage X
Community drainages X
Drainage booklet X X
Pleurodesis X X
Drain removal X X
AE data collection X X X X X X X X X X X
Chest X-ray X X X X X X X X* X X X X
Thoracic ultrasound X X X X X X X X
VAS assessment (pain and
breathlessness)
X X X X X X X
EORTC QLQ -C30 X X X X X X X
MRC Dyspnoea Score X X X X X X X
WHO performance status X
*Optional CXR based on USS appearances.
AE, adverse events; CXR, chest X-ray; IPC, indwelling pleural catheter; MRC, Medical Research Council; USS, ultrasound scan.
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A postinsertion chest X-ray will be performed to
conﬁrm the position of the catheter. Patients will be dis-
charged, and a district nurse referral completed if
required. Patients on steroids will be asked, if clinically
possible, to discontinue steroids 48 hours prior to their
visit on day 4 given the potential for talc slurry. In
steroid-dependent patients, admission to hospital prior
to pleurodesis will be at the discretion of the clinician as
per standard practice.
Patients will be reviewed on day 4 (±24 hours) postpro-
cedure. The pleural ﬂuid will be drained via the IPC.
The quantity of ﬂuid removed, and re-expansion of lung
will be assessed. If the average pleural ﬂuid output is low
(<150 mL/day) and if satisfactory re-expansion of lung is
conﬁrmed by ultrasound, talc pleurodesis will be
attempted through the IPC.
Satisfactory lung re-expansion will be deﬁned as lung
sliding on the chest wall in at least ﬁve of six deﬁned
areas in the chest (ﬁgure 2). In the case of uncertainty,
chest radiographs will be used. A diagnosis of lung
entrapment can be made using the pleural manometry
data, ultrasound and chest radiograph appearances. For
example, if uncertainty exists over potential small areas
of entrapment on ultrasound and the X-ray appearances
are satisfactory, talc may be administered.
If the lung has not re-expanded, continued
regular drainage (depending on ﬂuid output) will be
advised.
If talc pleurodesis is attempted based on the above cri-
teria, this will be administered as a ‘slurry’ via the IPC.
Then, 3 mg/kg (max 250 mg) 1% lignocaine will be
instilled into the pleural space via the IPC to prevent
any acute pain. This will be followed by 4 g of talc mixed
with 50 mL normal saline via the drain followed by
50 mL normal saline ﬂush. Patients will be observed for
at least 1 hour following talc instillation.
Figure 1 Trial pathway for the
indwelling pleural catheter group.
CXR, Chest X-ray; USS,
ultrasound scan; IPC, indwelling
pleural catheter; QoL, quality of
life.
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The patient will then be sent home with the advice to
drain daily with a 1 L vacuum bottle for 3 days. This can
be performed by themselves, their carer or district
nurse. They will be reviewed on the third day postpleur-
odesis (+48 hours). They will be asked to complete
health-related QoL and symptom questionnaires and
undergo ultrasound and chest X-ray review of the
pleural collection.
If there is no recurrence of effusion with satisfactory
ultrasound evidence of pleural symphysis in at least ﬁve
out of six areas, patients will be advised not to undertake
any drainage for further 7 days. On day 14 (±24 hours)
postintervention, they will undergo QoL and symptom
questionnaires, ultrasound and chest X-ray review. If
pleurodesis is successful, the IPC will be removed.
Successful pleurodesis will be deﬁned as pleural sym-
physis in at least ﬁve out of six areas (see ﬁgure 2) on
ultrasound as evidenced by the absence of lung sliding
in these areas.
Patients will undergo a clinic review at 30, 60 and
90 day’s postprocedure. At each visit, a chest X-ray and
chest ultrasound scan will be performed recording X-ray
appearances and the presence of pleural thickening,
depth of effusion and extent of septations on ultra-
sound. Patients will be required to complete the EORTC
QLQ-C30 questionnaire, MRC Dyspnoea Scale and VAS
for pain and breathlessness.
The usual care group
The usual care pathway is summarised in ﬁgure 3.
Patients randomised to the usual care group will be
managed according BTS guidelines. They will be admit-
ted to hospital for drain insertion and undergo a thor-
acic ultrasound to assess the pleura, pleural ﬂuid and to
identify a safe site for insertion. A standard 10 French—
14 French gauge chest drain will be inserted. Fluid will
be emptied gradually measuring oxygen saturations and
monitoring for symptoms. Pleural manometry will be
recorded.
From day 2 to 5 patients will be assessed for complica-
tions, drain output and lung re-expansion. If clinically
possible, any steroids will be discontinued. Once full
lung re-expansion is conﬁrmed on X-ray (deﬁned as full
re-expansion of the lung to the chest wall or only blunt-
ing of the costophrenic angle on the affected side), talc
slurry will be performed.
If lung re-expansion is unsatisfactory with evidence of
trapped lung on chest X-ray (<50% pleural apposition
on chest X-ray), then pleurodesis will not be attempted
and the drain removed with early follow-up of the
patient to consider repeated drainage of the effusion or
IPC insertion if symptomatic.
If pleurodesis is performed, it will be carried out as
per the BTS guidelines. Then, 3 mg/kg (maximum
250 mg) of 1% lignocaine will be administered via the
chest drain. This will be followed by 4 g talc mixed with
50 mL saline instilled through the drain, followed by
50 mL saline ﬂush of the drain into the pleural cavity.
The drain will be clamped and left closed for 1 hour.
After this time, the drain will be opened and left on free
drainage for 24–72 hours. If the ﬂuid output is <250 mL
per day, the drain will be removed and patient will be
discharged home. Complications, drain output and the
use of thoracic suction (which will be at the discretion
of the treating team) will be recorded. If the output is
high, the drain will be left longer and depending on the
clinical assessment as per the standard practice, the
drain will be removed.
Patients will have follow-up on the 7th day and 14th
day postprocedure. During each follow-up, they will
undergo a chest X-ray and chest ultrasound and be
asked to complete the QoL and symptom question-
naires. They will also undergo the same assessment at
follow-up 30, 60 and 90 days after the intervention. If
the pleurodesis is not successful, they will have further
assessment and will be managed based on clinical
requirement regarding the need for further pleural
intervention.
Figure 2 Sites of thoracic
ultrasound to assess for pleural
apposition.
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Patients may choose to withdraw themselves from the
trial. If a patient does so, we will retain the data the
patient has previously consented for us to collect and
analyse. No further data would be collected. It will be
made very clear to the patient throughout their
follow-up that a decision to withdraw from the trial will
not prejudice any future medical care they receive. On
completion of the trial, patients will receive normal
medical care as per local practices.
Sample size calculation and statistical analysis
In this ANCOVA study, sample sizes of 71 and 71 are
needed from each of the 2 groups whose means are to
be compared. The covariate has an R2 of 0.49 (0.7 cor-
relation between baseline and follow-up). A total sample
of 142 participants achieves 80% power to detect a clin-
ically signiﬁcant difference of 8 points in global health
status at 30 days among the means versus the alternative
of equal means using an F test with a 5% signiﬁcance
level. The minimally important difference in global
health status is based on reference values provided by
the EORTC Quality of Life Group.15 The common SD
within a group is assumed to be 23.60, derived from
EORTC reference values (all patients with cancer: stages
III and IV).15 Therefore, the randomisation target is 142
participants. The interim analysis is planned when 50%
of the randomisation target has been reached and will
include review of recruitment, follow-up rates and the
randomisation target.
Trial management
The respiratory research team at St Thomas’ hospital
will oversee site initiation and training, screening log
and data submission, data quality assurance and study
close out. The sponsor Guy’s and St Thomas’ Hospital
R&D development will oversee contracts agreements at
Figure 3 Trial pathway for the
usual care group. CXR, chest
X-ray; USS, ultrasound scan;
IPC, indwelling pleural catheter;
QoL, quality of life.
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each site. Sites will undergo regular monitoring by the
coordinating trial team (consisting of the chief investiga-
tor, trial manager and trial coordinator) through both
site visits as well as the assessment of submitted data
quality and adverse events (AEs). A yearly progress
report will also be submitted to the Health Research
Authority.
Data management
These data will be collected by the trial coordinator,
principal investigators and research nurse. Patient data
will be anonymised with trial number allocations. Data
will be recorded on paper case report forms in booklets
comprised of triplicate carbon copy paper. The data will
be analysed by the clinical research fellow, the chief
investigator and the trial statistician. This will primarily
be performed at St Thomas’ Hospital. This is an
18-month trial (total 3 months of follow-up) with subse-
quent data analysis and manuscript production. The
VAS Score will be measured by two members of the trial
team at the coordinating centre. Case Report Forms will
be stored in locked ﬁling cabinets. The completed case
reports forms will undergo quality control assessment
once the patient has completed or withdrawn from the
trial by the trial coordinator and manager before tran-
scription onto a password-protected database on a
secure computer network. This will performed by two
members of the trial team to ensure quality control and
data reliability. As this is a non-CTIMP trial, a data moni-
toring committee is not required; however, the interim
analysis will be performed by the trial statistician inde-
pendent of the investigators.
Adverse event reporting
Any serious adverse event (SAE) related to the study
procedures or is an unexpected occurrence (ie, the type
of event is not listed in the protocol as an expected
occurrence) must be reported immediately on knowl-
edge of the event to the sponsor within 24 hours. All
other AEs must be reported to the sponsor when copied
into the annual progress report. Given this is a multisite
trial, the principal investigators at all sites must report all
SAEs to the chief investigator ﬁrst where possible. The
chief investigator is responsible for reporting events to
the sponsor.
Expected AEs
These events are expected based on what is already
documented for events associated with the trial interven-
tions. The following are considered to be expected AEs
associated with the proposed interventions for this trial:
Chest drain and IPC insertion:
1. Pain at drain site
2. Localised bleeding at drain site
3. Localised infection at the drain site
4. Empyema
5. Pneumothorax
Talc pleurodesis
1. Pain
2. Fever
Other expected AEs
1. Death secondary to underlying malignancy
2. Hospitalisation due to underlying malignancy or
comorbid condition
These are well-acknowledged risks, and patients will be
consented appropriately. Participant safety will be
ensured through regular review and follow-up. During
the procedures, vital signs including blood pressure and
oxygen saturation measurements will be used to ensure
patient well-being. Chest X-ray will be used to verify tube
position.
ETHICS, APPROVALS AND DISSEMINATION
Regional Ethics Committee approval was granted by the
NRES Committee South East Coast—Brighton and
Sussex on the 22 June 2015 (reference 15/LO/1018).
Any important protocol modiﬁcations (such as
changes to the eligibility criteria, outcomes and ana-
lyses) that have been approved by the Health Research
Authority will be distributed to all principal investigators
and trial team members at each site. These will also be
communicated to the trial registries as well as journals at
the time of submission.
Approval was granted by the European Organisation
for Research and Treatment of Cancer for use of the
EORTC QLQ-C30 questionnaire.
We will disseminate the results regardless of outcome.
These will be broadcast to key stakeholders through con-
ference presentations and peer review journal
publications.
DISCUSSION
In the decision-making process, the impact of MPE on
health-related QoL, type and stage of underlying cancer,
performance status, prognosis and patient preference
should be considered. Part of the difﬁculty in evaluating
the comparative effectiveness of MPE treatments relates
to how outcomes are deﬁned in previous studies. QoL
assessments are infrequent and often not performed
with validated tools.
We outline the protocol and design of the Out
Patient Talc Slurry via Indwelling Pleural Catheter for
Malignant Pleural Effusion vs Usual Inpatient
Management (OPTIMUM) study. With a recruitment
target of 142 patients, this multicentre randomised con-
trolled trial is designed to detect a meaningful differ-
ence in global health status outcomes and will provide
key comparable data on health-related QoL outcomes
using an outpatient ambulatory pathway versus inpatient
chest drain insertion and pleurodesis in the manage-
ment of MPE.
Twitter Follow Parthipan Sivakumar at @d33pan
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